Published on 26 Mar 2022 on Benzinga via Yahoo Finance

Palisade Bio's LB1148 Cuts The Risk of Adhesion Formation By 72% After Bowel Resection Surgery

Palisade Bio Inc (NASDAQ: PALI) announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN), highlighting LB1148 reduced incidence of adhesions by 72% in patients undergoing bowel resection.

Studies assessed the efficacy of LB1148 to reduce the formation of adhesions in subjects undergoing abdominal surgery.Pooled data exhibited that LB1148 reduced the extent and severity of adhesions by 93% in patients undergoing bowel resection.The incidence of adhesions in the placebo group was similar to the published incidence (89% and ≥90%, respectively).Related: Palisade Bio Stock Shoots Up On FDA Fast Track Tag For LB1148 For Reduction of Post-Operative Adhesions.100% of placebo-treated subjects underwent a laparoscopic procedure, and 8 of 9 had ≥ 1 adhesions.75% of the 8 LB1148-treated subjects underwent a laparoscopic procedure, and 2 of 6 had ≥ 1 adhesions.No drug-related serious adverse events occurred in the trials.A total of 3/11 subjects in LBS-IST-POI-101 and 14/120 subjects in LBS-POI-201-CN underwent a second surgery.Price Action: PALI shares are down 14.40% at $1.01 during the market session on the last check Wednesday.